cGMP: Transition from bench to bedside: A report of the 6th International Conference on cGMP Generators, Effectors and Therapeutic Implications

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 387, Issue 8, 2014, Pages 707-718

  Hoffmann, Linda S ^a   Chen, Horng H ^b  

^a UNIVERSITY OF BONN   (Germany)

^b MAYO CLINIC   (United States)

Author keywords

Cardiovascular diseases; cGMP; Nitric oxide; Particulate guanylyl cyclase; sGC stimulator; Soluble guanylyl cyclase

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BACTERIAL PROTEIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLIC GMP; GUANYLATE CYCLASE; HEAT SHOCK PROTEIN 90; HEME; MICRORNA; MICRORNA 425; NITRIC OXIDE; PARTICULATE GUANYLYL CYCLASE; PROTEIN DISULFIDE ISOMERASE; PROTEIN EXOY; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SOLUBLE GUANYLYL CYCLASE; THYROID HORMONE; UNCLASSIFIED DRUG; CELL RECEPTOR; NATRIURETIC FACTOR;

3' UNTRANSLATED REGION; BACTERIAL GENOME; DISULFIDE BOND; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME CONFORMATION; ENZYME STRUCTURE; ENZYME SUBSTRATE COMPLEX; GENETIC ASSOCIATION; HAIR CELL; HEARING IMPAIRMENT; HEART FAILURE; HEART MUSCLE CELL; HNOX DOMAIN; HUMAN; MUSCLE RIGIDITY; MYOCARDIAL DISEASE; NONHUMAN; NONSHIVERING THERMOGENESIS; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN DOMAIN; PSEUDOMONAS AERUGINOSA; PULMONARY HYPERTENSION; REVIEW; SENSORY GANGLION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; WHITE ADIPOSE TISSUE; ANIMAL; BACTERIA; CHEMISTRY; METABOLISM; PROTEIN CONFORMATION;

ANIMALS; BACTERIA; CYCLIC GMP; GUANYLATE CYCLASE; HUMANS; NATRIURETIC PEPTIDES; NITRIC OXIDE; PROTEIN CONFORMATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84904326480     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-014-0999-8     Document Type: Review

References (55)

1. Allerston CK, von Delft F, Gileadi O (2013) Crystal structures of the catalytic domain of human soluble guanylate cyclase. PLoS One 8:e57644
2. Andersen MJ et al (2013) Sildenafil and diastolic dysfunction after acute myocardial infarction in patients with preserved ejection fraction: the Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (SIDAMI) trial. Circulation 127:1200-1208
3. Arora P et al (2013) Atrial natriuretic peptide is negatively regulated by microRNA-425. J Clin Invest 123:3378-3382
4. Bordicchia M et al (2012) Cardiac natriuretic peptides act via p38MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest 2012
5. Cannone V et al (2011) A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community. J Am Coll Cardiol 58:629-636
6. Cannone V et al (2013) The atrial natriuretic peptide genetic variant rs5068 is associated with a favorable cardiometabolic phenotype in a Mediterranean population. Diabetes 36:2850-2856
7. Chen HH, Grantham JA, Schirger JA, Jougasaki M, Redfield MM, Burnett JC Jr (2000) Subcutaneous administration of brain natriuretic peptide in experimental heart failure. J AmColl Cardiol 36:1706-1712
8. Chen HH, Glockner JF, Schirger JA, Cataliotti A, Redfield MM, Burnett JC Jr (2012a) Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. J Am Coll Cardiol 60:2305-2312
9. Chen W et al (2012b) Atrial natriuretic peptide enhances microvascular albumin permeability by the caveolae-mediated transcellular pathway. Cardiovasc Res 93:141-151
10. Chen W et al (2013) Atrial natriuretic peptide-mediated inhibition of microcirculatory endothelial Ca2+ and permeability response to histamine involves cGMP-dependent protein kinase I and TRPC6 channels. Arterioscler Thromb Vasc Biol 33:2121-2129
11. Coletta C et al (2012) Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angiogenesis and endothelium-dependent vasorelaxation. Proc Natl Acad Sci U S A 109:9161-9166
12. Derbyshire ER, Marletta MA (2012) Structure and regulation of soluble guanylate cyclase. Annu Rev Biochem 81:533-559
13. Ehret GB et al (2011) Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 478:103-109
14. Erdmann J et al (2013) Dysfunctional nitric oxide signalling increases risk of myocardial infarction. Nature 504:432-436
15. Frontini A, Cinti S (2010) Distribution and development of brown adipocytes in the murine and human adipose organ. Cell 11:253-256
16. Ghofrani HA et al (2013a) Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 369:319-329
17. Ghofrani HA et al (2013b) Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369:330-340
18. Ghosh A, Stuehr DJ (2012) Soluble guanylyl cyclase requires heat shock protein 90 for heme insertion during maturation of the NO-active enzyme. Proc Natl Acad Sci U S A 109:12998-13003
19. Gotz KR et al (2014) Transgenic mice for real-time visualization of cGMP in intact adult cardiomyocytes. Circ Res 114:1235-1245
20. Haas B et al (2009) Protein kinase g controls brown fat cell differentiation and mitochondrial biogenesis. Sci Signal 2:ra78
21. Hawkridge AM, Heublein DM, Bergen HR 3rd, Cataliotti A, Burnett JC Jr, Muddiman DC (2005) Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A 102:17442-17447 (Pubitemid 41740885)
22. Heckler EJ, Crassous PA, Baskaran P, Beuve A (2013) Protein disulfide-isomerase interacts with soluble guanylyl cyclase via a redox-based mechanism and modulates its activity. Biochem J 452:161-169
23. Jaumann M et al (2012) cGMP-Prkg1 signaling and Pde5 inhibition shelter cochlear hair cells and hearing function. Nat Med 18:252-259
24. Kajimura S, Saito M (2013) A new era in brown adipose tissue biology: molecular control of brown fat development and energy homeostasis. Annu Rev Physiol 76:225-249
25. Klein S et al (2013) Interstitial cells of Cajal integrate excitatory and inhibitory neurotransmission with intestinal slow-wave activity. Nat Commun 4:1630
26. Kumazoe M et al (2012) 67-kDa laminin receptor increases cGMP to induce cancer-selective apoptosis. J Clin Invest 123:787-799
27. Lee CY, Chen HH, Lisy O, Swan S, Cannon C, Lieu HD, Burnett JC Jr (2009) Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J Clin Pharmacol 49:668-673
28. Li P et al (2007) Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. Gastroenterology 133:599-607 (Pubitemid 47187356)
29. Lies B, Groneberg D, Friebe A (2013) Correlation of cellular expression with function of NO-sensitive guanylyl cyclase in the murine lower urinary tract. J Physiol 591:5365-5375
30. Liu N, Xu Y, Hossain S, Huang N, Coursolle D, Gralnick JA, Boon EM (2012) Nitric oxide regulation of cyclic di-GMP synthesis and hydrolysis in Shewanella woodyi. Biochemistry 51:2087-2099
31. Lukowski R, Rybalkin SD, Loga F, Leiss V, Beavo JA, Hofmann F (2010) Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes. Proc Natl Acad Sci U S A 107:5646-5651
32. Mitrovic V, Jovanovic A, Lehinant S (2011) Soluble guanylate cyclase modulators in heart failure. Curr Heart Fail Rep 8:38-44
33. Mitschke MM et al (2013) Increased cGMP promotes healthy expansion and browning of white adipose tissue. FASEB J 2013:9
34. Mittendorf J et al (2009)Discovery of riociguat (BAY63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem 4:853-865
35. Nakagawa Y et al (2014) The effects of super-flux (high performance) dialyzer on plasma glycosylated pro-B-type natriuretic peptide (proBNP) and glycosylated N-terminal proBNP in end-stage renal disease patients on dialysis. PLoS One 9:e92314
36. Nedergaard J, Cannon B (2010) The changed metabolic world with human brown adipose tissue: therapeutic visions. Cell Metab 11:268-272
37. Newton-Cheh C et al (2009) Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet 41:348-353
38. Pfeifer A, Kilic A, Hoffmann LS (2013) Regulation of metabolism by cGMP. Pharmacol Ther 140:81-91
39. Prysyazhna O, Rudyk O, Eaton P (2012) Single atom substitution in mouse protein kinase G eliminates oxidant sensing to cause hypertension. Nat Med 18:286-290
40. Rangaswami H et al (2010) Cyclic GMP and protein kinase G control a Src-containing mechanosome in osteoblasts. Sci Signal 3:2001423
41. Redfield MM et al (2013) Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 309:1268-1277
42. Robinson JW, Potter LR (2012) Guanylyl cyclases A and B are asymmetric dimers that are allosterically activated by ATP binding to the catalytic domain. Sci Signal 5:2003253
43. Rose RA (2010) CD-NP, a chimeric natriuretic peptide for the treatment of heart failure. Curr 11:349-356
44. Rudyk O, Prysyazhna O, Burgoyne JR, Eaton P (2012) Nitroglycerin fails to lower blood pressure in redox-dead Cys42Ser PKG1alpha knock-in mouse. Circulation 126:287-295
45. Rudyk O, Phinikaridou A, Prysyazhna O, Burgoyne JR, Botnar RM, Eaton P (2013) Protein kinase G oxidation is a major cause of injury during sepsis. Proc Natl Acad Sci U S A 110:9909-9913
46. Salvi E et al (2012) Genomewide association study using a high-density single nucleotide polymorphism array and case-control design identifies a novel essential hypertension susceptibility locus in the promoter region of endothelial NO synthase. Hypertension 59:248-255
47. Stasch JP, Pacher P, Evgenov OV (2011) Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 123:2263-2273
48. Takimoto E et al (2005) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11:214-222 (Pubitemid 40321358)
49. Ter-Avetisyan G, Rathjen FG, Schmidt H (2014) Bifurcation of axons from cranial sensory neurons is disabled in the absence of Npr2-induced cGMP signaling. J Neurosci 34:737-747
50. Thunemann M et al (2013) Transgenic mice for cGMP imaging. Circ Res 113:365-371
51. Tsai EJ et al (2012) Pressure-overload-induced subcellular relocalization/oxidation of soluble guanylyl cyclase in the heart modulates enzyme stimulation. Circ Res 110:295-303
52. Underbakke ES, Iavarone AT, Marletta MA (2013) Higher-order interactions bridge the nitric oxide receptor and catalytic domains of soluble guanylate cyclase. Proc Natl Acad Sci U S A 110:6777-6782
53. Valentino MA et al (2011) A uroguanylin-GUCY2C endocrine axis regulates feeding in mice. J Clin Invest 121:3578-3588
54. van Heerebeek L et al (2012) Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation 126:830-839
55. Yamada-Goto N et al (2013) Intracerebroventricular administration of Ctype natriuretic peptide suppresses food intake via activation of the melanocortin system in mice. Diabetes 62:1500-1504